Related Experiment Video
Updated: Aug 23, 2026

Synthesis of Nine-atom Deltahedral Zintl Ions of Germanium and their Functionalization with Organic Groups
Published on: February 11, 2012
AN-9 (Titan)
1Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
Abstract:
Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients with liver tumors was initiated. By November 2001, enrollment had been completed in a second phase II study of refractory non-small-cell lung cancer (NSCLC). In June 2003, Titan began enrollment for a phase IIb trial of AN-9 in combination with docetaxel in patients with NSCLC.
Insights
AN-9, a novel histone deacetylase inhibitor, shows potential in treating liver tumors and non-small-cell lung cancer (NSCLC). Clinical trials are evaluating its efficacy and combination therapy for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Titan is developing AN-9, a histone deacetylase (HDAC) inhibitor analog of butyric acid.
- AN-9 induces apoptosis in cancer cells by signaling cellular differentiation.
- HDAC inhibitors represent a promising class of anticancer agents.
Purpose of the Study:
- To evaluate the safety and efficacy of AN-9 in patients with various cancers.
- To explore AN-9 as a monotherapy and in combination with docetaxel for non-small-cell lung cancer (NSCLC).
- To assess the potential of AN-9 in treating liver tumors.
Main Methods:
- Phase I/II study initiated in March 2001 for liver tumors.
- Phase II study completed enrollment by November 2001 for refractory NSCLC.
- Phase IIb trial initiated in June 2003 for NSCLC, combining AN-9 with docetaxel.
Main Results:
- Enrollment completed for Phase I/II and Phase II studies.
- Phase IIb trial commenced, indicating ongoing clinical investigation.
- Specific efficacy and safety results are pending further trial data.
Conclusions:
- AN-9 demonstrates potential as an anticancer therapeutic agent.
- Further clinical trials are necessary to establish the full efficacy and safety profile of AN-9.
- Combination therapy with docetaxel is being investigated for advanced NSCLC.
Related Concept Videos
Dimensional Analysis
Conversion Factors and Dimensional Analysis
The unit...
Acids, Bases and Neutralization Reactions
Electrolysis
Free Energy and Equilibrium
Recall that Q is the numerical value of the mass action expression...
Le Chatelier's Principle: Changing Concentration
Precipitation Reactions

